Here, as stated above, we will focus on the severe end of the dystrophinopathy spectrum, i.e., DMD, synthetically defined as severe dystrophinopathy with absent, or at most trace amounts of dystrophin protein expression; and we will aim to summarize current knowledge regarding the molecular bases of DMD phenotypic variability. This evidence concerns the gene DMD and Duchenne muscular dystrophy.